News: Portfolio 2007

Schering-Plough and OraSure Technologies Sign Agreement for Development and Promotion of Rapid Point-of-Care Oral Hepatitis C Test

Test Will Utilize OraSure's OraQuick(R) Technology Platform

January 4, 2007: - KENILWORTH, N.J. and BETHLEHEM, Pa., /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) and OraSure Technologies, Inc. (Nasdaq: OSUR) today announced an agreement to collaborate on the development and promotion of a rapid oral test for the detection of antibodies to the hepatitis C virus (HCV) utilizing OraSure Technologies' OraQuick(R) technology platform.

 

The agreement brings together OraSure - the leader in oral fluid diagnostics and developer and manufacturer of the OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody Test, the first and only U.S. Food and Drug Administration (FDA) approved rapid oral fluid HIV-1/2 Test, and Schering-Plough Corporation, a worldwide leader in the discovery and development of novel HCV therapies.

 

 

 

"As a long-term innovator and leader in the hepatitis therapy area, Schering-Plough is the ideal partner to help us introduce our rapid, point-of- care oral HCV test to the U.S. physicians' office market once our product receives FDA approval. We believe a rapid oral fluid HCV test has significant commercial and medical value in that it will help identify more individuals who are infected, thus enabling them to receive appropriate treatment. We look forward to a long and successful collaboration with Schering-Plough on this important product," said Douglas A. Michels, President and CEO of OraSure Technologies.

 

Page: 1 2 3 4 5 6 7